Treatment with the ROS-inducing agent menadione causes a decrease in Akt phosphorylation and subsequent cell death in pancreatic cancer cells, which is mediated by the disruption of the Ras-PI3K-Akt pathway [31,32]. The gene discussed is AKT1; the disease is pancreatic neoplasm.